


Oxaliplatin-d₁₀

Cat. No.:	HY-17371S
CAS No.:	1132819-16-9
Molecular Formula:	C ₈ H ₄ D ₁₀ N ₂ O ₄ Pt
Molecular Weight:	407.35
Target:	Isotope-Labeled Compounds
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Oxaliplatin-d ₁₀ is a deuterium labeled Oxaliplatin (HY-17371). Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research ^{[1][2][3]} .
In Vitro	<p>Caution: Product has not been fully validated for medical applications. For research use only. Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019 Feb;53(2):211-246.
- [2]. Garrett MJ, et al. Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer. *Hosp Pharm*. 2017 May;52(5):341-347.
- [3]. Yi Yao, et al. Comparative proteomic analysis of colon cancer cells in response to oxaliplatin treatment. *Biochim Biophys Acta*. 2009 Oct;1794(10):1433-40.
- [4]. Park GY, et al. Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile. *Proc Natl Acad Sci U S A*. 2012 Jul 24;109(30):11987-92.
- [5]. Mohammed MQ, et al. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with NSC 119875 and NSC 241240. *Anticancer Drugs*. 2000 Nov;11(10):859-63.
- [6]. Raymond E, et al. Oxaliplatin: a review of preclinical and clinical studies. *Ann Oncol*. 1998 Oct;9(10):1053-71.
- [7]. Wang Z, et al. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth. *Expert Opin Investig Drugs*. 2009 Nov;18(11):1595-604
- [8]. Pendyala L, et al. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. *Cancer Res*. 1993 Dec 15;53(24):5970-6.
- [9]. Mathé G, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum. *Biomed Pharmacother*. 1989;43(4):237-50.
- [10]. Schellingerhout D, et al. Impairment of retrograde neuronal transport in oxaliplatin-induced neuropathy demonstrated by molecular imaging. *PLoS One*. 2012;7(9):e45776. doi: 10.1371/journal.pone.0045776. Epub 2012 Sep 20.